Literature DB >> 11263857

Expression of the non-classical HLA-G antigen in tumor cell lines is extremely restricted.

K Poláková1, G Russ.   

Abstract

It has been proposed that tumor cells frequently associated with partial or total loss of HLA class Ia expression may abnormally express HLA-G class Ib antigen. Such peculiar HLA class I expression would allow tumor cells to escape not only from CD8+T but also from NK-cell cytotoxicity. We studied the cell surface expression of HLA-G using flow cytometry with two HLA-G specific monoclonal antibodies (87G, 01G). The JEG-3 choriocarcinoma cell line, which constitutively expresses HLA-G antigens was used as a positive control. We did not detect the cell-surface HLA-G antigens in the following 75 tumor cell lines: melanoma (22), neuroblastoma (7), retinoblastoma (1), glioma (2), breast carcinoma (3), ovarian carcinoma (3), cervical carcinoma (1), colon carcinoma (3), bladder carcinoma (2), hepatocarcinoma (1), sarcoma (2) and leukemia cell lines: T-lymphocytes (6), B-lymphocytes (13) and myelo-monocytes (9). We found that some myelomonocytic cell lines express on their surface high affinity FcgammaRI (CD64) that may result in the binding of HLA-G specific mabs to their cell surface even in the absence of HLA-G molecules. Our panel of HLA-G negative tumor cell lines accommodated 62 cell lines for which similar analysis have not been reported and also contained 13 cell lines with total or partial loss of HLA class Ia molecules. Our observation imply that under normal culture conditions the cell surface HLA-G reactive with 87G and 01G mabs is absent in most tumor cell lines of different origin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11263857

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  HLA-G gene repression is reversed by demethylation.

Authors:  Philippe Moreau; Gael Mouillot; Philippe Rousseau; Celine Marcou; Jean Dausset; Edgardo D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

2.  Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding.

Authors:  Roberta Rizzo; Alessandro Trentini; Daria Bortolotti; Maria C Manfrinato; Antonella Rotola; Massimiliano Castellazzi; Loredana Melchiorri; Dario Di Luca; Franco Dallocchio; Enrico Fainardi; Tiziana Bellini
Journal:  Mol Cell Biochem       Date:  2013-06-05       Impact factor: 3.396

3.  Synthetic HLA-G proteins for therapeutic use in transplantation.

Authors:  Joel LeMaoult; Marina Daouya; Juan Wu; Maria Loustau; Anatolij Horuzsko; Edgardo D Carosella
Journal:  FASEB J       Date:  2013-06-10       Impact factor: 5.191

4.  Trogocytic intercellular membrane exchanges among hematological tumors.

Authors:  Joel LeMaoult; Julien Caumartin; Marina Daouya; Magdalena Switala; Vera Rebmann; Bertrand Arnulf; Edgardo D Carosella
Journal:  J Hematol Oncol       Date:  2015-03-14       Impact factor: 17.388

5.  Characterization of HLA-G Regulation and HLA Expression in Breast Cancer and Malignant Melanoma Cell Lines upon IFN-γ Stimulation and Inhibition of DNA Methylation.

Authors:  Nanna Jørgensen; Abid Sayed; Helene Bjerregaard Jeppesen; Gry Persson; Iben Weisdorf; Tina Funck; Thomas Vauvert Faurschou Hviid
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

6.  Interleukin 10 Induces the Expression of Membrane-Bound HLA- G and the Production of Soluble HLA-G on HeLa CCL-2 Cells.

Authors:  Nurul Hasanah; Karyono Mintaroem; Loeki Enggar Fitri; Noorhamdani Noorhamdani
Journal:  Open Access Maced J Med Sci       Date:  2019-10-14

7.  Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis.

Authors:  Anna Gillio-Tos; Maria da Graça Bicalho; Valentina Fiano; Chiara Grasso; Valentina Tarallo; Laura De Marco; Morena Trevisan; Marinabarbaradesousa Xavier; Renata Slowik; Newton S Carvalho; Carlos A Maestri; Hadriano M Lacerda; Daniela Zugna; Lorenzo Richiardi; Franco Merletti
Journal:  BMC Cancer       Date:  2012-12-24       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.